FibroGen Inc (FGEN)
1.125
0.00 (0.00%)
USD |
NASDAQ |
May 03, 16:00
1.125
0.00 (0.00%)
After-Hours: 20:00
FibroGen Cash and Short Term Investments (Quarterly): 235.59M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 235.59M |
| September 30, 2023 | 191.24M |
| June 30, 2023 | 335.72M |
| March 31, 2023 | 355.95M |
| December 31, 2022 | 422.01M |
| September 30, 2022 | 408.52M |
| June 30, 2022 | 438.13M |
| March 31, 2022 | 428.08M |
| December 31, 2021 | 405.19M |
| September 30, 2021 | 486.40M |
| June 30, 2021 | 507.21M |
| March 31, 2021 | 544.23M |
| December 31, 2020 | 686.54M |
| September 30, 2020 | 687.87M |
| June 30, 2020 | 685.59M |
| March 31, 2020 | 535.43M |
| December 31, 2019 | 533.76M |
| September 30, 2019 | 628.63M |
| June 30, 2019 | 660.76M |
| March 31, 2019 | 565.40M |
| Date | Value |
|---|---|
| December 31, 2018 | 621.40M |
| September 30, 2018 | 652.73M |
| June 30, 2018 | 671.90M |
| March 31, 2018 | 703.77M |
| December 31, 2017 | 735.72M |
| September 30, 2017 | 729.97M |
| June 30, 2017 | 359.40M |
| March 31, 2017 | 243.42M |
| December 31, 2016 | 253.18M |
| September 30, 2016 | 241.80M |
| June 30, 2016 | 230.52M |
| March 31, 2016 | 173.41M |
| December 31, 2015 | 181.17M |
| September 30, 2015 | 221.52M |
| June 30, 2015 | 248.66M |
| March 31, 2015 | 142.69M |
| December 31, 2014 | 179.82M |
| September 30, 2014 | 175.50M |
| June 30, 2014 | 202.09M |
| December 31, 2013 | 122.81M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
191.24M
Minimum
Sep 2023
687.87M
Maximum
Sep 2020
482.99M
Average
486.40M
Median
Sep 2021
Cash and Short Term Investments (Quarterly) Benchmarks
| Annovis Bio Inc | 5.755M |
| Emergent BioSolutions Inc | 111.70M |
| Geron Corp | 333.70M |
| Vertex Pharmaceuticals Inc | 11.22B |
| Regulus Therapeutics Inc | 23.77M |